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Abstract
Background: Osteochondral talar defects usually affect athletic patients. The primary surgical
treatment consists of arthroscopic debridement and microfracturing. Although this is mostly
successful, early sport resumption is difficult to achieve, and it can take up to one year to obtain
clinical improvement. Pulsed electromagnetic fields (PEMFs) may be effective for talar defects after
arthroscopic treatment by promoting tissue healing, suppressing inflammation, and relieving pain.
We hypothesize that PEMF-treatment compared to sham-treatment after arthroscopy will lead to
earlier resumption of sports, and aim at 25% increase in patients that resume sports.
Methods/Design: A prospective, double-blind, randomized, placebo-controlled trial (RCT) will
be conducted in five centers throughout the Netherlands and Belgium. 68 patients will be
randomized to either active PEMF-treatment or sham-treatment for 60 days, four hours daily. They
will be followed-up for one year. The combined primary outcome measures are (a) the percentage
of patients that resume and maintain sports, and (b) the time to resumption of sports, defined by
the Ankle Activity Score. Secondary outcome measures include resumption of work, subjective and
objective scoring systems (American Orthopaedic Foot and Ankle Society – Ankle-Hindfoot Scale,
Foot Ankle Outcome Score, Numeric Rating Scales of pain and satisfaction, EuroQol-5D), and
computed tomography. Time to resumption of sports will be analyzed using Kaplan-Meier curves
and log-rank tests.
Discussion: This trial will provide level-1 evidence on the effectiveness of PEMFs in the
management of osteochondral ankle lesions after arthroscopy.
Trial registration: Netherlands Trial Register (NTR1636)
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Osteochondral defects (ODs) of the talus often have a
severe impact on the quality of life of the patients. The
patients are usually young and athletic; most are male
(62%) in the third decade of their lives after a traumatic
ankle sprain [1]. The primary treatment of a symptomatic
OD consists of arthroscopic debridement and microfrac-
turing [2]. This treatment yields 87% good or excellent
results [3]. However, it can take up to one year to obtain
improvement of clinical symptoms. Moreover, it is a great
challenge to achieve early resumption of sports, which is
the main goal of many of these young patients. In a series
published in 2007, 26 "high-demand" athletic patients
with an OD returned to sports at a mean of 15 weeks after
debridement and microfracturing [4]. If we could shorten
this period, we would considerably improve the quality of
life in these active patients.
A potential solution to obtain this goal is the application
of pulsed electromagnetic fields (PEMFs). Bassett in the
1960s and 1970s introduced and improved the clinical
use of this treatment modality [5,6]. Since then, PEMFs
have been applied increasingly, including their use in the
treatment of osteoarthritis and (non-united) fractures
[7,8]. They are designed as a portable PEMF generator,
which consists of electromagnetic fields with an on-off
effect of pulsing. This produces athermal effects that sup-
press inflammation, promote tissue healing, and relieve
pain [9]. In vitro and in vivo studies have shown that
PEMFs act as adenosine A2a agonists, leading to an
increase of Transforming Growth Factor β-1, thereby
improving bone development, reducing cartilage damage
and increasing chondrocyte proliferation [10-21]. These
results clearly indicate improved regeneration of bone and
possibly cartilage in a scientific setting.
Clinically, its favorable effects are less obvious. PEMF as a
solitary treatment for osteoarthritis of the knee has been
repeatedly investigated, with conflicting results [7,22-25].
Although the effect of PEMFs on osteoarthritis of the knee
seems equivocal, their value in the additional treatment of
other bony and cartilaginous pathologies is promising.
PEMFs have been proven as a successful method in frac-
ture healing, especially in the case of non-union
[8,26,27]. PEMF-treatment also favors the recovery of
patients after arthroscopic treatment of chondral lesions
in the knee, and reduces the use of non-steroidal anti-
inflammatory drugs [28]. To our knowledge, sport
resumption with the use of PEMFs has not been investi-
gated. Based on the above data, we believe that PEMFs
may act on ODs by improving bone regeneration and sup-
pressing inflammation evoked by surgery.
When the above results are combined, it seems justified to
state that additional PEMF-treatment may contribute to
the management of ODs. Our study question is: "Does
treatment with PEMFs compared to sham device lead to
earlier resumption of sports in a higher percentage of
patients with an osteochondral defect of the talus after
arthroscopic debridement and microfracturing?".
Methods/Design
Study design and informed consent
The study is designed as a double-blind, randomized, pla-
cebo controlled, multicenter trial, which is in accordance
with the Declaration of Helsinki [29]. The methodology
will follow CONSORT (Consolidation of Standards of
Reporting Trials) guidelines [30,31]. Five centers in the
Netherlands and Belgium will participate. Approval has
been obtained from the local Medical Ethics Committees
in the participating centers (MEC 08/236). Written
informed consent for participation in the study will be
obtained from all patients at study entry. An information
letter notifying the patients' participation will be sent to
their general practitioners.
Randomization
The participants will be randomized to receive either
active PEMF-treatment or sham device, stratified for par-
ticipating center, body mass index (≤/> 25 kg/m2) [32,33],
and diameter of the defect on computed tomography
(CT) (≤/> 10 mm) [1]. Randomization will be performed
in randomly allocated blocks of two or four patients using
ALEA, a validated web-based computer program [34]. The
provider of the PEMF-devices (IGEAmedical, Carpi, Italy)
will supply an equal number of active and sham devices
identified by code numbers which correspond to the ran-
domization program. Treatment allocation will be man-
aged by an independent, unblinded research assistant
(IS), who will not be involved in patient care or assess-
ment. Patients and treating physicians as well as medical
assessors will be blinded to the allocation of treatment.
The code numbers will not be broken until all patients
have completed the study.
Inclusion criteria
• Patients with a symptomatic OD of the talus who are
scheduled for arthroscopic debridement and microf-
racture [2]
• OD diameter < 15 mm on CT (in three dimensions:
medial-lateral, anterior-posterior and superior-infe-
rior)
• Ankle Activity Score (AAS) ≥ 4 before symptoms
(Table 1) [35]
• Age 18 years or older
Exclusion criteria
• Concomitant OD of the tibiaPage 2 of 10
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Ankle Activity Scorea
Category Sports and Activities T C R
10 American football 10 9 8
Basketball 10 9 8
Gymnastics 10 9 8
Handball 10 9 8
Rugby 10 9 8
Soccer 10 9 8
9 Hockey 9 8 7
Korfball 9 8 7
Martial arts: judo, karate, kung fu, taekwondo 9 8 7
Orienteering 9 8 7
Rhythmic gymnastics 9 8 7
Volleyball 9 8 7
8 Boxing 8 7 6
Freestyle snowboarding 8 7 6
Ice hockey 8 7 6
Tennis 8 7 6
Wrestling 8 7 6
7 Aerobics, fitness 7 6 5
Badminton 7 6 5
Baseball 7 6 5
Cross-country running (running on uneven ground) 7 6 5
Modern pentathlon 7 6 5
Squash 7 6 5
Surfing, windsurfing 7 6 5
Table tennis 7 6 5
Track and field: field events 7 6 5
Water skiing 7 6 5
6 Dancing 6 5 4
Fencing 6 5 4
Floorball 6 5 4
Mountain and hill climbing 6 5 4
Nordic skiing 6 5 4
Parachuting 6 5 4
Softball 6 5 4
Special professions and working activitiesb 6
5 Diving 5 5 4
Scuba diving 5 5 4
Skating, in-line skating 5 5 4
Track and field: track events (running on even ground) 5 5 4
Triathlon 5 5 4
Weightlifting, body building 5 5 4
All competitive sports of categories 4 and 3 with seasonal conditioning 5
Heavy physical work 5
4 Alpine skiing and snowboarding 4 4 4
Bowling/curling 4 4 4
Golf 4 4 4
Mountain biking/bmx 4 4 4
Power lifting 4 4 4
Sailing 4 4 4
Physical work 4
3 Cycling 3 3 3
Equestrian 3 3 3
Motorsports, technical sports 3 3 3
Rowing, kayaking 3 3 3
Shooting, archery 3 3 3
Water polo and swimming 3 3 3
Able to walk on any uneven ground 3Page 3 of 10
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• Ankle fracture < 6 months before scheduled arthros-
copy
• Surgical treatment of the index ankle performed < 1
year before scheduled arthroscopy
• Concomitant painful or disabling disease of the
lower limb
• Rheumatoid arthritis
• Pregnancy
• Implanted pacemaker
• Participation in concurrent trials
• Participation in previous trials < 1 year, in which the
subject has been exposed to radiation (radiographs or
CT)
• Patients who are unable to fill out questionnaires
and cannot have them filled out
• No informed consent
Device description
PEMFs are applied using a portable generator attached to
the ankle (Figure 1). The coil in the active treatment
device generates a peak magnetic field intensity of 1.5 mT,
supplied by an electric pulse frequency of 75 Hz [37]. The
sham devices do not differ from active devices in shape,
color, weight, and in acoustic or visual signaling. Neither
the active nor the sham device produces noise or sensa-
tion and they are entirely indistinguishable. The only dif-
ference is the generated magnetic field; the sham device
produces a negligible peak of less than 0.05 mT, supplied
by the minimal current necessary to power the device
indicators.
Standard treatment and investigational treatment
All surgical procedures will be performed using a stand-
ardized technique [2]. Briefly, the ankle joint is
approached by arthroscopy using an anterior or posterior
approach. The OD is identified with a probe and debrided
with a curette and bonecutter shaver. All unstable bone
and cartilage are removed. After full debridement, the
subchondral bone is perforated with a microfracture awl,
with intervals of approximately 3 mm. At the end of the
procedure a pressure bandage is applied.
After surgery the protocol-based rehabilitation program,
guided by a physiotherapist, will be equal in both groups.
It will be initiated with partial (eggshell) weight bearing
on crutches, as tolerated, and progressed to full weight
bearing over a period of six weeks. During this period
active non-weight-bearing and partial weight-bearing sag-
ittal range of motion exercises are encouraged, i.e., 15
minutes twice daily. After this six week' period, resump-
tion of sports will be permitted as tolerated, and will not
be directed by the clinician.
In both groups the investigational treatment (active
PEMF-treatment or sham device treatment) will start
within three days after surgery. It will be applied four
hours daily (in one or two sessions) for a period of 60
days [37,38]. The patients' compliance will be monitored
by a clock inside the device that records the hours of stim-
ulation.
The prescription of nonsteroidal anti-inflammatory drugs
will be avoided due to their negative effect on bone regen-
eration [39]. The use of paracetamol will be allowed up to
a maximum dose of 4 g/d and will be discontinued one
week before the visits at baseline, 1 month, 2 months, 6
months and 1 year.
Outcome measures
The combined primary outcome measures are:
(a) the number of patients that resume and maintain
sports during 12 months follow-up, and
(b) the time to resumption of sports, defined by the
AAS.
Secondary outcome measures are:
- time to resumption of work,
2 No sports, everyday activities not limited 2
1 Able to walk on even ground, but everyday activities limited 1
0 Unable to walk, disabled because of ankle problems 0
aT, top level (international elite, professional, national team, or first division); C, lower competitive levels; R, recreational level (participation should 
be considered only if it exceeds 50 hours per year).
bSpecial professions include ballet dancer, professional soldier, special rescue worker, stuntperson, and so forth.
If multiple options are applicable, the highest level is chosen.
Table 1: Ankle Activity Score by Halasi et al. [35] (Continued)Page 4 of 10
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Ankle-Hindfoot Scale (AOFAS-AHS),
- Foot and Ankle Outcome Score (FAOS),
- quality of life (EuroQol-5D),
- pain (Numeric Rating Scale),
- satisfaction (Numeric Rating Scale),
- computed tomography, and
- adverse events.
Definitions
Primary outcome measures
Because there is no consensus as to defining what actual
resumption of sport is – as Saxena and Eakin stated [4] –
we define time to resumption of sports as the time after
arthroscopy (weeks) until initiation of any sport with a
minimum level of the pre-symptoms level minus 1 point
on AAS, and maintained for at least 30 days. If a patient's
activity level decreases to below the minimum level
within 30 days after sport resumption, the resumption
date will not be counted. To evaluate the level of sport
activity, we will use the AAS that has been developed and
validated by Halasi and associates [35]. This 10-point
score is based on the type and level of sport or work, with
0 points indicating the lowest activity and 10 points indi-
cating the highest activity (Table 1).
Secondary outcome measures
Resumption of work is defined as the ability to perform
normal work exercises without any deficits in work qual-
ity [40]. The AOFAS-AHS is a frequently used combined
objective-subjective 100-point scale which devotes 40
points to pain, 50 points to function, and 10 points to
alignment [41]. The subjective part was recently validated
[42]. The FAOS is a subjective 42-item questionnaire
assessing five subscales: pain, other symptoms, activities
of daily living, sports, and quality of life. All items are
scored on a Likert-scale, and each of the five subscales is
transformed to a score of 0 (worst) to 100 (best). The orig-
inal English version has been validated [43], and the
Dutch translation is currently being validated in our insti-
tution. The EuroQol (EQ-5D) is a validated and exten-
sively used general health questionnaire to measure
quality of life [44,45]. It comprises five dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension is marked as either
no problems, some problems, or severe problems, which
results in a 1-digit number expressing the level selected for
that dimension. The digits for five dimensions are com-
bined in a 5-digit number describing the respondent's
health state. The numeric rating scale (NRS) for pain con-
sists of an 11-point scale (0 – 10) which represents the
whole spectrum of no pain up to the worst pain imagina-
ble [46]. Pain at rest and pain when running will be meas-
ured. Patients' satisfaction will be measured using a NRS
where 0 indicates no satisfaction and 10 indicates maxi-
mally possible satisfaction.
To objectively assess bone repair we will obtain multislice
helical CT-scans of the affected ankles at baseline and one
year after surgery (Figure 2). CT-scanning has been proven
to be accurate in the detection and follow-up of ODs of
the talus, regarding location and extent as well as healing
of the defect [47,48]. The scanning protocol will involve
"ultra high resolution" axial slices with an increment of
The application of pulsed electromagnetic fields on the ankle, generated in the green coil and attached with the elastic band(I-ONE, IGEAmedica , Carpi, It ly)Figu e 1
The application of pulsed electromagnetic fields on 
the ankle, generated in the green coil and attached 
with the elastic band (I-ONE, IGEAmedical, Carpi, 
Italy).Page 5 of 10
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coronal and sagittal reconstructions of 1 mm [49]. The
scans will be analyzed twice by a single physician, blinded
to both treatment allocation and clinical outcome, meas-
uring completeness, thickness, and level of the subchon-
dral plate (i.e., flush, depressed, or proud) [50].
Additionally, bone volume filling of the defect after one
year will be measured, and graded as good (67% to
100%), moderate (34% to 66%), or poor (0% to 33%)
[51].
Adverse events
Any (serious) adverse event during the trial period will be
recorded. Adverse events are defined as any undesirable
experience occurring to a subject during a clinical trial,
whether or not considered related to the investigational
treatment, e.g. infection, numbness, or paraesthesia. A
serious adverse event (SAE) is any undesirable experience
associated with the use of the investigational treatment
that results in death, is life threatening (at the time of the
event), requires hospitalization or prolongation of exist-
ing inpatients' hospitalization, or results in persistent or
clinically relevant disability or incapacity. All SAEs will be
reported to the central Medical Ethics Committee accord-
ing to their requirements. Patients suffering from a SAE
will stop their PEMF- or sham-treatment.
Data collection
For each randomized patient a specially designed digital
Case Report Form (CRF) will be completed. The CRF con-
sists of a sequential set of instructions with provision for
data recording. Internet-based remote data capture will be
used for entering, managing and validating data from the
investigative sites. For this purpose Oracle Clinical will be
used, a program designed to meet industry regulations,
including FDA 21CFR Part 11 Rule (March 20, 1997),
ICH; Good Clinical Practice: Consolidated Guideline
(May 9, 1997) and FDA Guidance for Industry "Compu-
terized Systems Used In Clinical Trials" (May 10, 1999).
All randomized patients are identified by a Patient Identi-
fication Number (PIN) in combination with a center
number. Trial personnel will not pass names outside the
local hospitals. The investigator will ensure that patients'
anonymity is maintained. On CRFs or other documents
submitted to the coordinating center, patients will not be
identified by their names but by a PIN in combination
with a center number. The subject identification code list
will be safeguarded by the investigator.
Data acquisition and follow-up
Participating patients will be assessed at the following
time points (Table 2):
1. Preoperatively: information letter, informed consent,
baseline characteristics (age, gender, weight, height,
affected side, duration of symptoms, past medical his-
tory, smoking status), type of sport and profession,
AAS (2×: before symptoms and at preoperative assess-
ment), AOFAS-AHS, FAOS, EQ-5D, NRS pain (2×: at
rest and when running), CT: size, localization and
classification of the OD (Table 3) [52]
2. 1–2 weeks postoperatively: check compliance, (S)AEs,
wound inspection (healing, signs of infection)
3. 1 month postoperatively: check compliance, (S)AEs,
resumption of work, EQ-5D, NRS pain (at rest) and
satisfaction
4. 2 months postoperatively: check compliance, (S)AEs,
resumption of sport and work, AAS, AOFAS-AHS,
FAOS, EQ-5D, NRS pain (at rest and when running, if
applicable) and satisfaction, wound inspection, stop
PEMF- or sham-treatment
5. 6 months postoperatively: resumption and mainte-
nance of sport and work, AAS, EQ-5D, NRS pain (at
rest and when running)
6. 1 year postoperatively: resumption and maintenance
of sport and work, AAS, AOFAS-AHS, FAOS, EQ-5D,
NRS pain (at rest and when running) and satisfaction,
(S)AEs, CT: subchondral plate and bone volume fill-
ing
Recording sport resumption
To assess the resumption of sports and work, the patients
will keep a diary that will be supplied at inclusion. Every
time they perform sports they will record the type of sport
and activity level (i.e., professional, competitive, or recre-
ational) in this diary. They will also record the resumption
of work, as defined above. This diary will be used for the
monitoring of resumption and maintenance of sports and
activity levels. At the postoperative visits the patients will
Preoperative computed tomography (axial, coronal, and sag-ittal slices) of the left ankle of a 25-year-old female showing a typical o e ch ndral ef ct loc ted on the post romedial al r dome (arrows)Figur  2
Preoperative computed tomography (axial, coronal, 
and sagittal slices) of the left ankle of a 25-year-old 
female showing a typical osteochondral defect 
located on the posteromedial talar dome (arrows).Page 6 of 10
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ities and work resumption, to be filled out on the CRF. At
one year the diary will be collected for assessment and
confirmation of resumption dates.
Sample size
Our sample size calculation is based on the combined pri-
mary endpoints (a) number of patients that resume and
maintain sports during 12 months follow-up, and (b) the
time to resumption of sport. Based on our experience it is
expected that 50% of patients will resume and maintain
sports within one year after the surgical intervention.
Offering additional PEMF-treatment, we aim to improve
this outcome to 75%. Of the patients who resume to sport
the mean time to return to sports after debridement and
microfracturing is 15 (standard deviation, 4 weeks) [4].
We consider a 20% reduction in time to return to sports as
clinically relevant, i.e., 3 weeks. A sample size of 30
patients in each group (60 patients in total) will have 80%
power to detect a joint difference (control group propor-
tion of 0.50 versus treatment proportion of 0.75; control
group mean of 15 weeks versus treatment group mean of
12, assuming a common standard deviation of 4), using a
Fisher's combination test with a 0.05 two-sided signifi-
cance level. In reported clinical trials with this device 9%
to 13% of included patients dropped out [28,38]. There-
fore, 34 patients will be included in each treatment group
(68 patients in total).
Statistical methods
The following baseline characteristics will be summarized
using descriptive statistics: number of patients, gender,
age, affected side, duration of symptoms (months), prior
ankle surgery, body mass index (kg/m2), trauma, smok-
ing, size of lesion (mm), classification, duration of PEMF-
or sham-treatment (hours), AAS, NRS pain, FAOS,
AOFAS-AHS, and EQ-5D. Continuous data will be pre-
sented as mean and standard deviation if normally dis-
tributed, or as median and range in case of skewed
distribution.
The main analysis of this trial consists of a comparison
between the treatment groups of the primary outcomes:
number of patients who resume and maintain sports and
the time to resumption of sport (of the patients who
resume sport). The number of patients who resume sport
will be analyzed using the two group X2 test, whereas the
difference in mean weeks to sport resumption will be ana-
Table 2: Patient assessment.
Physician Patient
Baseline 
character
istics*
Sport 
resumpti
on
Work 
resumpti
on
AAS AOFAS-
AHS
CT Wound 
inspectio
n
Complia
nce
Adverse 
events
FAOS EQ-5D NRS pain NRS 
satisfacti
on
Preoper
ative
X X X X X X X
1–2 
weeks
X X X
1 
month
X X X X X X
2 
months
X X X X X X X X X X X
6 
months
X X X X X
1 year X X X X X X X X X X
* Baseline characteristics include age, gender, weight, height, affected side, duration of symptoms, type of sport and profession, past medical history, 
smoking status, and size, localization and classification of osteochondral defect on computed tomography.
AAS = Ankle Activity Score; AOFAS-AHS = American Orthopaedic Foot and Ankle Society – Ankle-Hindfoot Scale; CT = Computed Tomography; 
FAOS = Foot and Ankle Outcome Score; EQ-5D = EuroQol questionnaire; NRS = Numeric Rating Scale.
Table 3: Computed tomography classification of osteochondral 
defects of the talus [52].
Grade Description
I Compression
II Partially fractured but undisplaced
III Completely fractured but undisplaced
IV Displaced fracture
V Radiolucent (fibrous) defectPage 7 of 10
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combined using the Fisher's combination test. Kaplan-
Meier survival curves and the log-rank test will also be
used for comparing time to resumption of sport. The strat-
ification variables will be included in the primary analy-
sis.
The repeated datastructure of the secondary outcomes
(AAS, AOFAS-AHS, FAOS, EQ-5D, NRS-pain, and NRS-
satisfaction) will be analyzed with linear mixed models,
including a time-treatment interaction effect. The number
of adverse events and time to resumption of work will be
analyzed using a Χ2 test or log-rank test, when appropri-
ate. Analyses will be based on the intention-to-treat prin-
ciple and performed in SPSS. Statistical uncertainty will be
quantified via 95% confidence intervals.
Participating centers and inclusion time
Centers that will participate and their estimated annual
inclusions are:
1. Academic Medical Center, Amsterdam, the Netherlands
(Prof. Dr. C.N. van Dijk and Dr. G.M.M.J. Kerkhoffs): 24
patients
2. Erasmus MC, University Medical Center Rotterdam, the
Netherlands (Dr. D.E. Meuffels and Dr. R. Heijboer): 20
patients
3. Stedelijk Ziekenhuis Roeselare, Belgium (Dr. P.R.N.
d'Hooghe): 8 patients
4. Diaconessenhuis, Leiden, the Netherlands (Dr. R.
Krips): 8 patients
5. Algemeen Ziekenhuis Sint Lucas, Brugge, Belgium (Dr.
G. van Damme): 8 patients
It will take an estimated year to include 68 patients. With
one year follow-up, this trial will take an expected two
years to be performed.
Quality assurance
A clinical research associate from our Clinical Research
Unit will monitor the trial. All centers will be monitored
twice: after the fourth included patient after two months
follow-up and after the last patient's last visit. Monitoring
will consist of 100% check informed consent procedure,
registration of adverse events, completeness of the trial
master file, and verification of source data (primary out-
come in 10% sample).
Public disclosure and publication policy
This trial has been registered in the Netherlands Trial Reg-
ister (NTR1636). Publication will be in accordance with
the basic principles of the International Committee of
Medical Journal Editors on publication policy [53]. The
writing committee will consist of the following people:
C.J.A. van Bergen, L. Blankevoort, R.J. de Haan, and C.N.
van Dijk. All principal investigators at the participating
centers will have the opportunity to scientifically contrib-
ute to the manuscript, and, if so, will be listed as an
author. If they do not wish to contribute to the manu-
script, they will be acknowledged in the order of the
number of participants randomized. Other individuals
who make substantial contributions to the trial will be
acknowledged at the discretion of the writing committee.
Discussion
This paper describes the rationale and study protocol for
conducting a double-blind, randomized controlled trial
on the effectiveness of PEMF in the rehabilitation of ankle
arthroscopy for ODs of the talus.
The primary outcome measure focuses on sport resump-
tion. This is a difficult measure – as several authors wrote
previously [4,54,55] – since a univocal definition does
not exist. By clearly defining sport resumption, we aim at
providing evidence of any relevant differences between
active and passive PEMF-treatment. Moreover, if our defi-
nition shows to be useful in the present study, it can be
used for the design of future trials.
Regarding the treatment of ODs of the talus, we consider
bone regeneration more important than cartilage regener-
ation. Cartilage is not innervated; the patient's pain prob-
ably arises from the bony lesion [56]. Additionally, a
differentiation can be made between ODs localized in the
ankle joint and those localized in the knee joint. Most
studies concerning ODs of the knee focus on cartilage
repair rather than bone repair [57,58]. This seems reason-
able since the knee joint is less congruent and the ODs are
usually localized in high-load-bearing areas. Moreover,
the knee joint is more susceptible to osteo-arthritis than
the ankle joint [59,60]. The ankle joint, however, has dif-
ferent biomechanical properties. The joint is more con-
gruent and talar articular cartilage is thinner than distal
femoral cartilage [61]. The load-bearing contact surface of
the ankle joint is somewhat larger [62-64], and the OD is
often smaller. Hence, the remaining intact surface of the
talar dome is usually sufficiently large to bear the loads;
contact surface pressures do not significantly change with
talar defects up to 15 mm in diameter [65]. Combining
these properties, we believe treatment of ODs in the ankle
joint should primarily aim at repair of the subchondral
bone, and secondarily at coverage by fibrocartilaginous
tissue. In this respect, PEMF-treatment may be particularly
suitable for ODs of the talus since its bone-healing capac-
ity has been proven [8,26,27,66].
This trial will contribute to the knowledge of the effective-
ness of PEMF, and may improve health care of patientsPage 8 of 10
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2009, 10:83 http://www.biomedcentral.com/1471-2474/10/83with an OD. Given the modality's relatively simple tech-
nology and ease of use, it has high potential to provide a
safe and effective additional treatment option for ODs of
the talus.
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